Deacon CF - Search Results

1

The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.

Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C, Rizza RA, Vella A. Bock G, et al. Among authors: deacon cf. Clin Endocrinol (Oxf). 2010 Aug;73(2):189-96. doi: 10.1111/j.1365-2265.2009.03764.x. Epub 2009 Dec 18. Clin Endocrinol (Oxf). 2010. PMID: 20039889 Free PMC article. Clinical Trial.

2

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon CF, Johnsen AH, Holst JJ. Deacon CF, et al. J Clin Endocrinol Metab. 1995 Mar;80(3):952-7. doi: 10.1210/jcem.80.3.7883856. J Clin Endocrinol Metab. 1995. PMID: 7883856

3

Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma.

Pridal L, Deacon CF, Kirk O, Christensen JV, Carr RD, Holst JJ. Pridal L, et al. Among authors: deacon cf. Eur J Drug Metab Pharmacokinet. 1996 Jan-Mar;21(1):51-9. doi: 10.1007/BF03190278. Eur J Drug Metab Pharmacokinet. 1996. PMID: 8839678

4

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.

Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Deacon CF, et al. Diabetologia. 1998 Mar;41(3):271-8. doi: 10.1007/s001250050903. Diabetologia. 1998. PMID: 9541166

5

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

Deacon CF, Hughes TE, Holst JJ. Deacon CF, et al. Diabetes. 1998 May;47(5):764-9. doi: 10.2337/diabetes.47.5.764. Diabetes. 1998. PMID: 9588448

6

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

Holst JJ, Deacon CF. Holst JJ, et al. Among authors: deacon cf. Diabetes. 1998 Nov;47(11):1663-70. doi: 10.2337/diabetes.47.11.1663. Diabetes. 1998. PMID: 9792533 Review.

7

On the treatment of diabetes mellitus with glucagon-like peptide-1.

Holst JJ, Deacon C, Toft-Nielsen MB, Bjerre-Knudsen L. Holst JJ, et al. Ann N Y Acad Sci. 1998 Dec 11;865:336-43. doi: 10.1111/j.1749-6632.1998.tb11193.x. Ann N Y Acad Sci. 1998. PMID: 9928027 Review.

8

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

Hansen L, Deacon CF, Orskov C, Holst JJ. Hansen L, et al. Among authors: deacon cf. Endocrinology. 1999 Nov;140(11):5356-63. doi: 10.1210/endo.140.11.7143. Endocrinology. 1999. PMID: 10537167

9

In vivo and in vitro degradation of glucagon-like peptide-2 in humans.

Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ. Hartmann B, et al. Among authors: deacon cf. J Clin Endocrinol Metab. 2000 Aug;85(8):2884-8. doi: 10.1210/jcem.85.8.6717. J Clin Endocrinol Metab. 2000. PMID: 10946898

10

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Deacon CF, et al. J Clin Endocrinol Metab. 2000 Oct;85(10):3575-81. doi: 10.1210/jcem.85.10.6855. J Clin Endocrinol Metab. 2000. PMID: 11061504 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Search Page

Filters